Symptomdx.

Get Started

Transfusion-Related Acute Lung Injury (TRALI)MANAGEMENT

HEMATOLOGIC AND ONCOLOGIC PRESENTATIONS · 12 SECTIONS

⚲

755 items

☷ Legend

⚲

Cardiovascular Presentations71▾

Respiratory Presentations52▾

Neurological Presentations83▾

Gastrointestinal Presentations74▾

Genitourinary and Reproductive Presentations48▾

Infectious Disease Presentations148▾

Trauma Presentations89▾

Toxicologic Presentations80▾

Psychiatric Presentations26▾

Musculoskeletal and Rheumatologic Presentations96▾

Dermatology Presentations23▾

Environmental and Exposure Presentations27▾

Hematologic and Oncologic Presentations36▾

Acute chest syndrome Acute Hemolytic Transfusion Reaction Anticoagulant reversal (warfarin, DOAC, heparin)Aplastic Anemia (Crisis)Autoimmune Hemolytic Anemia CAR-T and cytokine release syndrome Coagulopathy Delayed Hemolytic Transfusion Reaction Disseminated Intravascular Coagulation (DIC)Essential Thrombocythemia Febrile Non-hemolytic Transfusion Reaction Graft Versus Host Disease (Acute)Hemolytic Uremic Syndrome (HUS)Hemophilia A (Bleeding Crisis)Heparin-Induced Thrombocytopenia (HIT)Hyperviscosity syndrome Immune checkpoint inhibitor toxicity Immune Thrombocytopenic Purpura (ITP)Leukemoid Reaction Leukostasis Massive transfusion protocol Myelofibrosis Neutropenic enterocolitis (typhlitis)Paroxysmal Nocturnal Hemoglobinuria Polycythemia Vera (Crisis)Pure Red Cell Aplasia Sickle Cell (Acute Chest Syndrome)Sickle Cell (Splenic Sequestration)Sickle cell crisis (vaso-occlusive)Symptomatic anemia Thrombocytopenia (severe)Thrombotic Thrombocytopenic Purpura (TTP)Transfusion-Associated Circulatory Overload (TACO)Transfusion-Related Acute Lung Injury (TRALI)Tumor lysis syndrome Von Willebrand Disease (Bleeding)

Pediatric-Specific Presentations19▾

Endocrine and Metabolic Presentations45▾

ENT and Maxillofacial Presentations27▾

Ophthalmologic Presentations19▾

Obstetric Presentations23▾

Systemic and Miscellaneous Presentations17▾

01Approach to the Critical Patient/attcp59

Immediate resuscitation priorities

›Airway and oxygenation

›Stop transfusion immediately — first and most critical intervention

›Maintain IV access with normal saline

›Do NOT discard the blood product — return to blood bank for investigation

›Supplemental oxygen titration

›SpO2 target >92% initially

›Escalate delivery device: nasal cannula to simple mask to non-rebreather

›Respiratory failure threshold

›PaO2/FiO2 ratio <=300 mmHg defines acute lung injury

›PaO2/FiO2 ratio <=200 mmHg defines severe ARDS

›If SpO2 not maintained on high-flow oxygen, escalate immediately

›High-flow nasal cannula (HFNC) first-line escalation

›Intubation if HFNC fails or patient tires

›Hemodynamic stabilization

›Fluid management

›Restrictive fluid strategy — avoid aggressive IV fluids

›Non-cardiogenic pulmonary edema — diuretics are contraindicated

›Vasopressor threshold

›MAP <65 mmHg refractory to conservative fluid resuscitation

›Norepinephrine first-line vasopressor

›Cardiovascular differentiation

›Hypotension suggests TRALI (not TACO)

›Hypertension with JVD and elevated BNP suggests TACO

›Mechanical ventilation if intubated

›Lung-protective strategy per ARDS protocol

›Tidal volume 6 mL/kg ideal body weight

›Plateau pressure <30 cmH2O

02History/hx69

Transfusion context

›Blood product details

›Type of product transfused

›Packed red blood cells (pRBCs)

›Fresh frozen plasma (FFP) — highest plasma volume risk

›Apheresis platelets — high risk if from female donors

›Whole blood or cryoprecipitate

›Transfusion timing

›Onset during transfusion vs within 6 hours after

›Volume transfused and number of units

›Donor characteristics if known

›Female donor with prior pregnancy history

›Multiparous donors carry ~24% prevalence of HLA antibodies

›Symptom onset and progression

›Temporal relationship to transfusion

›Onset during transfusion (most common)

›Onset within 6 hours post-transfusion

›Delayed onset up to 72 hours (atypical)

›Respiratory symptoms

›Acute dyspnea — rapidly progressive

›Cough with frothy or pink-tinged sputum

›Chest tightness

›Systemic symptoms

›Fever and rigors present in approximately 30% of cases

›Chills or flushing

Risk factor assessment

›Recipient first-hit risk factors

›Recent surgery

03Physical Exam/exam64

Vital signs

›Hemodynamic profile

›Blood pressure

›Hypotension — SBP <90 mmHg distinguishes from TACO

›MAP <65 mmHg indicates shock

›Heart rate

›Tachycardia >100 bpm from hypoxemia and inflammation

›Temperature

›Fever present in ~30% of TRALI cases

›High fever with rigors may also suggest septic transfusion reaction

›Respiratory rate

›Tachypnea >20 typically present

›>= 30 per minute severe respiratory compromise

›Oxygen saturation

›Hypoxemia on pulse oximetry correlating with ABG

Pulmonary exam

›Auscultation findings

›Bilateral crackles/rales

›Diffuse distribution consistent with permeability edema

›Distinguishes from focal infection pattern

›Reduced or absent breath sounds

›Severe pulmonary edema

›Assess for pleural effusion at bases

›Work of breathing

›Accessory muscle use

›Intercostal and supraclavicular retractions

›Inability to complete full sentences

›Airway assessment

04Differential Diagnosis/ddx53

Life-threatening transfusion reactions

›Transfusion-associated circulatory overload (TACO)

›ICD-10: E87.70 (fluid overload, unspecified)

›Cardiogenic/hydrostatic pulmonary edema

›Elevated BNP/NT-proBNP significantly elevated

›Hypertension, JVD, S3 gallop, peripheral edema

›Responds to diuretics

›Most important diagnostic mimic of TRALI

›Septic transfusion reaction

›Bacterial contamination of blood product

›High fever >38.5 C with rigors

›Gram-negative septicemia pattern

›Blood cultures of product and patient are diagnostic

›Platelets highest risk — stored at room temperature

›Acute hemolytic transfusion reaction

›ABO incompatibility

›Flank or back pain

›Hemoglobinuria — port-wine urine

›DIC development

›Positive DAT (direct antiglobulin test)

›Anaphylactic transfusion reaction

›IgA deficiency most common predisposing factor

›Urticaria, angioedema, bronchospasm, hypotension

›Onset within minutes of transfusion start

›Absent fever distinguishes from TRALI

Non-cardiogenic pulmonary edema mimics

›Acute respiratory distress syndrome from other causes

›ICD-10: J80

05Laboratory Tests/lt68

Arterial blood gas

›ABG analysis

›PaO2/FiO2 ratio calculation

›<=300 mmHg required for TRALI diagnosis

›<=200 mmHg — severe ARDS category

›pH and PaCO2

›Respiratory alkalosis early (tachypnea compensation)

›Respiratory acidosis with ventilatory failure

›Serial ABG

›Trend PaO2/FiO2 to assess response to treatment

›Guide ventilator adjustments if intubated

Complete blood count

›CBC interpretation

›Leukopenia

›Transient leukopenia relatively specific for TRALI

›Neutrophil sequestration in pulmonary vasculature

›May normalize within hours

›Thrombocytopenia

›Platelet consumption in severe cases

›DIC overlap if hemolytic reaction coexists

›Hemoglobin

›Baseline and post-transfusion levels

›Hemolysis pattern if concurrent hemolytic reaction

Biomarkers for TRALI vs TACO differentiation

›BNP or NT-proBNP

›TRALI pattern

›Normal or mildly elevated BNP in TRALI

›Key differentiating biomarker from TACO

06Diagnostic Tests/dt69

Scoring Systems

›TRALI diagnostic criteria (National Heart Lung Blood Institute 2019 consensus)

›TRALI Type I criteria

›No pre-existing acute lung injury before transfusion

›Acute onset during or within 6 hours of transfusion

›PaO2/FiO2 <=300 mmHg or SpO2 <90% on room air

›Bilateral infiltrates on frontal chest radiograph

›No evidence of circulatory overload (TACO) as primary cause

›TRALI Type II criteria

›Pre-existing ARDS risk factor present

›Stable respiratory status in the 12 hours prior to transfusion

›Worsening meets criteria above within 6 hours of transfusion

›Possible TRALI

›Clinical criteria met but no implicated donor antibody identified

›Non-immune mechanism suspected (bioactive lipids)

›TACO diagnostic criteria (for comparison)

›New or worsening respiratory distress within 6 hours of transfusion

›Evidence of positive fluid balance

›Elevated BNP/NT-proBNP

›Hypertension and JVD

›Radiographic evidence of pulmonary edema consistent with cardiogenic cause

›TRALI severity classification

›Mild — supplemental oxygen only required

›Moderate — HFNC or NIV required

›Severe — mechanical ventilation or ECMO required

›Mortality by severity

›Overall mortality 6-12%

›Critically ill patients exceed 40% mortality

MRI

›Chest MRI in TRALI

›Not a primary diagnostic modality for TRALI

›Impractical in acute respiratory failure

›Critically ill patients cannot tolerate scan

›Potential role if diagnosis unclear after stabilization

›Bilateral ground glass opacities on MRI

›Differentiation from fibrosis or other parenchymal disease

›Rarely used in clinical practice

›CT and CXR remain first-line imaging modalities

›MRI reserved for persistent unexplained bilateral infiltrates post-recovery

›Chest CT in TRALI

›Indications

›Atypical or delayed presentation when diagnosis uncertain

›Exclusion of PE when bilateral infiltrates not explained by TRALI

›Assessment of underlying pulmonary pathology

›Classic CT findings

›Bilateral ground glass opacities

›Diffuse alveolar consolidation predominantly in dependent regions

›Absence of cardiomegaly and pleural effusions (distinguishes from TACO)

›CT pulmonary angiography (CTPA)

›If pulmonary embolism in differential

›Bilateral infiltrates plus hypoxemia without clear transfusion immune trigger

›Limitation

›CT not required for TRALI diagnosis in typical presentation

›CXR sufficient for initial diagnosis confirmation

Ultrasound

›Point-of-care ultrasound (POCUS) for TRALI vs TACO

›Lung ultrasound

›B-lines in bilateral lung zones — consistent with pulmonary edema (both TRALI and TACO)

›Bilateral B-lines without pleural consolidation typical of permeability edema

›Cannot reliably differentiate TRALI from TACO on lung findings alone

›Cardiac ultrasound

›Left ventricular function assessment

›Preserved or hyperdynamic LV function in TRALI

›Reduced LV function or diastolic dysfunction suggests TACO

›IVC plethora and dilated RA/RV suggests volume overload (TACO)

›POCUS clinical utility

›Rapid bedside differentiation of TRALI from TACO

›Avoids delay to treatment while awaiting BNP results

›Class IIa recommendation for bedside cardiac POCUS in undifferentiated pulmonary edema

›Inferior vena cava assessment

›IVC diameter <2 cm with respiratory variation — low right-sided pressures (TRALI)

›IVC >2 cm without collapse — elevated right-sided pressures (TACO)

07Disposition/dispo40

ICU admission criteria

›Mandatory ICU indications

›Respiratory failure requiring intubation

›Mechanical ventilation with lung-protective strategy

›Sedation and paralysis requirement

›Hemodynamic instability requiring vasopressors

›Norepinephrine or vasopressin infusion

›Arterial line and central venous access

›Severe hypoxemia not controlled on HFNC

›PaO2/FiO2 <=200 mmHg despite initial oxygen therapy

›ECMO candidacy

›Refractory hypoxemia on maximal conventional ventilation

Step-down and monitored bed

›Intermediate care criteria

›Mild TRALI stabilizing on supplemental oxygen

›SpO2 maintaining >92% on <=6L nasal cannula

›Hemodynamically stable without vasopressors

›Minimum 24-hour monitoring

›Even mild cases require minimum 24 hours of observation

›Potential for delayed worsening in first 24 hours

›Telemetry monitoring

›Continuous cardiac rhythm monitoring

›Hourly vital signs and oxygen saturation

Transfer criteria

›Transfer indications

›Escalating ECMO requirement beyond local capability

›Transfer to ECMO-capable center if refractory hypoxemia

›Complex transfusion medicine needs

08Treatment/t111

Stop transfusion and preserve product

›Immediate interventions

›Stop transfusion — first action for any suspected TRALI

›Maintain IV access with normal saline at same site

›Do NOT discard the blood product

›Blood product handling

›Return product to blood bank in original bag

›Notify blood bank with clinical details immediately

›Retain all associated tubing and filters for investigation

›Documentation

›Time transfusion stopped relative to symptom onset

›Volume transfused prior to reaction

›Blood product type, lot number, and unit identification

Oxygen therapy

›Oxygen escalation ladder

›Nasal cannula 1-6 L/min

›SpO2 target >92%

›Step up if target not achieved

›Simple face mask 5-10 L/min

›Delivers FiO2 up to 0.50

›Step up if inadequate

›Non-rebreather mask 10-15 L/min

›FiO2 up to 0.90

›Short-term bridge to HFNC or intubation

›High-flow nasal cannula (HFNC)

›Flow rate 30-60 L/min

›FiO2 up to 1.0

›Reduces work of breathing and provides mild CPAP effect

›First-line escalation before intubation

Mechanical ventilation

›Intubation indications

›Respiratory failure unresponsive to HFNC

›PaO2/FiO2 <=150 mmHg despite HFNC at maximum settings

›Increasing work of breathing with fatigue

›Hemodynamic instability requiring rapid sequence intubation

›Lung-protective ventilation settings

›Tidal volume 6 mL/kg ideal body weight

›Calculate IBW: male 50 + 2.3 x (height in inches - 60); female 45.5 + 2.3 x (height in inches - 60)

›Never exceed 8 mL/kg IBW

›Plateau pressure <30 cmH2O

›Driving pressure target <15 cmH2O

›PEEP titration

›ARDSnet low PEEP/FiO2 table as starting point

›Titrate to oxygenation target SpO2 88-95%

›FiO2 titration

›Wean to lowest FiO2 maintaining SpO2 >88%

›Prone positioning

›Consider if PaO2/FiO2 <=150 mmHg on optimized ventilator settings

›16-18 hours prone per cycle per PROSEVA protocol

›Mortality benefit demonstrated in ARDS (Class I recommendation)

Vasopressor support

›Vasopressor therapy for refractory hypotension

›Norepinephrine (first-line)

›Initial dose 0.01-0.03 mcg/kg/min IV infusion

›Titrate by 0.01-0.05 mcg/kg/min every 5-10 minutes

›Target MAP >=65 mmHg

›Doses >0.25 mcg/kg/min indicate severe shock

›Vasopressin (adjunct to norepinephrine)

›Fixed dose 0.03-0.04 units/min IV infusion

›Do not titrate — fixed dose only

›Add when norepinephrine >0.25 mcg/kg/min

›Epinephrine (third-line)

›Initial dose 0.01 mcg/kg/min IV

›Titrate to hemodynamic response

›Use when vasopressin and norepinephrine insufficient

›Central venous access required for vasopressor infusion

›Internal jugular, subclavian, or femoral approach

›Arterial line placement for continuous MAP monitoring

Fluid management

›Restrictive fluid strategy

›Avoid aggressive IV fluid resuscitation

›Non-cardiogenic edema — excessive fluids worsen pulmonary edema

›Target euvolemia or slight negative balance after stabilization

›Conservative ARDS fluid strategy (consistent with FACTT trial)

›Target CVP 4-6 mmHg if measured

›Target PAOP 8-12 mmHg if PA catheter in place

›Fluid balance target: neutral to -500 mL/day after stabilization

›Avoid diuretics unless TACO component confirmed

›Diuretics contraindicated in pure TRALI — worsen hypotension

›If TACO overlap suspected, use cautiously with hemodynamic monitoring

Contraindicated and unproven treatments

›Medications to avoid

›Diuretics — contraindicated in TRALI

›Non-cardiogenic edema mechanism — diuresis does not improve alveolar edema

›Worsens hypotension and reduces cardiac output

›Corticosteroids — not routinely recommended

›No proven benefit in clinical trials (Class IIb, insufficient evidence)

›May be considered in individual refractory cases — no guideline support

›Antihistamines — ineffective for TRALI

›May have role in concurrent allergic or anaphylactic reaction only

›ECMO

›Veno-venous ECMO for refractory hypoxemia

›Indication: PaO2/FiO2 <80 mmHg on optimized ventilation

›Murray score >3 or pH <7.20 after optimization

›Transfer to ECMO center if not available locally

Prevention of future TRALI

›Donor-side prevention strategies

›Male-only donor plasma policy

›Plasma from male donors eliminates HLA antibody risk

›Implemented in multiple national blood systems with significant TRALI reduction

›Female apheresis platelet donor screening

›Screen for anti-HLA and anti-HNA antibodies

›Defer antibody-positive donors from platelet donation

›Implicated donor management

›Permanently defer implicated donor from plasma-containing product donation

›Notify donor of deferral reason

›Recipient-side prevention strategies

›Restrictive transfusion threshold

›Hemoglobin trigger <=70 g/L in stable, non-cardiac patients (Class I, multiple RCT support)

›Avoid unnecessary transfusion — each unit increases TRALI risk

›Alternative plasma products

›Prothrombin complex concentrates instead of FFP when appropriate

›Fibrinogen concentrate instead of cryoprecipitate

›Reduces plasma volume exposure

›Future transfusion planning for prior TRALI patient

›Document reaction in medical record permanently

›Use male donor products or antibody-screened donors

›Avoid products from implicated donor

09Special Populations/sp64

Pregnancy

›TRALI in pregnant patients

›Physiologic vulnerability

›Physiologic anemia of pregnancy increases transfusion exposure

›Obstetric hemorrhage — massive transfusion protocol increases TRALI risk

›Peripartum cardiomyopathy overlap can mimic TACO

›Risk profile

›Massive transfusion in obstetric hemorrhage — multiple plasma-rich units

›FFP and platelet transfusion during DIC of obstetric hemorrhage

›OR 4.5 for TRALI with FFP from female multiparous donors

›Management modifications

›Standard lung-protective ventilation applies

›Fetal monitoring if viable fetus

›Obstetric team involvement for simultaneous maternal-fetal management

›Vasopressors: norepinephrine preferred over dopamine in pregnancy

›Diuretics contraindicated as in non-pregnant TRALI

›Uteroplacental perfusion may be impaired by maternal hypotension

Geriatric

›TRALI in older adults

›Increased baseline risk factors

›Higher rates of cardiac disease — TACO differentiation more complex

›Reduced respiratory reserve — rapid progression to respiratory failure

›More frequent transfusion exposure — increased cumulative risk

›Diagnostic challenges

›Pre-existing diastolic dysfunction elevates baseline BNP

›BNP less reliable for TRALI vs TACO differentiation

›Baseline pulmonary disease may obscure new bilateral infiltrates

›Management considerations

10Background/b92

Epidemiology

›Incidence and prevalence

›TRALI incidence per transfused patient

›Estimated 1 in 5000 to 1 in 10,000 transfused units (varies by product type)

›FFP incidence approximately 1 in 7900 units

›Apheresis platelets from female donors highest individual unit risk

›TRALI as leading cause of transfusion mortality

›Leading cause of transfusion-related death in many countries including the US

›Accounts for approximately 30-50% of all transfusion-related deaths reported to FDA

›Population at risk

›ICU patients with multiple risk factors have incidence up to 1-5%

›Critically ill patients mortality exceeds 40%

›Overall mortality 6-12%

›Impact of male-only donor plasma policy

›Significant reduction in TRALI incidence in countries implementing male-only plasma

›UK blood service reported >50% reduction after policy implementation

›Temporal trends

›Declining incidence in countries with active donor screening programs

›Male-only plasma programs reduce immune-mediated TRALI

›Non-immune TRALI persists due to bioactive lipid accumulation in stored products

›Recovery timeline

›Most survivors recover within 48-96 hours

›Radiographic clearance expected within 4 days in survivors

›No permanent pulmonary sequelae expected in survivors

Pathophysiology

›Two-hit model of TRALI

›First hit — recipient priming

›Endothelial activation and neutrophil priming in pulmonary vasculature

›Causes: sepsis, surgery, trauma, mechanical ventilation, massive transfusion, chronic alcohol use, positive fluid balance

›IL-8 elevation as biomarker of neutrophil priming state

›Second hit — transfusion trigger

›Immune-mediated pathway (Type I TRALI — most common mechanism)

›Donor anti-HLA class I or class II antibodies bind recipient leukocyte antigens

›Donor anti-HNA antibodies bind recipient neutrophil antigens (HNA-3a most severe)

›Antibody-antigen complex activates complement and neutrophils

›Neutrophil degranulation releases reactive oxygen species and proteases

›Disruption of pulmonary endothelial and alveolar barrier

›Protein-rich exudate floods alveolar spaces

›Non-immune pathway (biologically active lipids)

›Lysophosphatidylcholines accumulate in stored blood products

›Direct neutrophil activation and endothelial injury

›Increases with storage duration of cellular blood products

›Explains TRALI cases without identifiable donor antibody

›Pulmonary pathology

›Neutrophil sequestration in pulmonary capillaries

›First-pass sequestration due to anatomic lung position

›Enhanced by primed state from first hit

›Alveolar-capillary barrier disruption

›Protein-rich (exudative) pulmonary edema

›Alveolar edema fluid protein-to-plasma ratio >0.75

›Surfactant dysfunction from protein flooding

›Transient leukopenia mechanism

›Neutrophil sequestration in pulmonary vasculature causes peripheral leukopenia

›Transient — resolves as sequestration resolves

›Donor antibody epidemiology

›Anti-HLA prevalence in multiparous women approximately 24%

›Prior pregnancy sensitizes immune system to paternal HLA antigens

›OR 4.5 for TRALI from female multiparous donor plasma

›Anti-HNA-3a antibodies

›Highest-affinity antibodies — associated with most severe TRALI

›Cause fatal TRALI even without first-hit priming

Therapeutic Considerations

›Evidence base for current treatment

›Lung-protective ventilation

›ARDS Network landmark trial (ARDSnet) established 6 mL/kg IBW benefit

›22% relative mortality reduction vs conventional ventilation

›Direct extrapolation to TRALI-associated ARDS (Class I recommendation)

›Prone positioning

›PROSEVA trial demonstrated 42.8% vs 32.8% 28-day survival benefit (p=0.02)

›Applicable when PaO2/FiO2 <=150 mmHg — Class I recommendation

›Conservative fluid management

›FACTT trial: conservative strategy improved oxygenation index without mortality increase

›Fewer ventilator days in conservative fluid group

›HFNC in acute hypoxemic respiratory failure

›FLORALI trial: HFNC reduced 90-day mortality vs NIV in hypoxemic respiratory failure

›Applicable to non-intubated TRALI patients

›Absence of proven TRALI-specific therapies

›Diuretics

›Multiple retrospective series confirm no benefit and potential harm

›Worsen hypotension without improving lung edema

›Corticosteroids

›No RCT evidence supports routine use in TRALI

›Animal models suggest possible benefit — no human trial data

›Class IIb — may be considered in individual refractory cases

›Emerging therapies under investigation

›Mesenchymal stromal cells — preclinical benefit in TRALI models

›IL-6 and IL-10 biomarkers for early differentiation of TRALI from TACO

›Extracellular vesicles as therapeutic targets

›Prevention evidence

›Restrictive transfusion threshold

›Multiple RCTs confirm hemoglobin trigger <=70 g/L safe in non-cardiac patients

›Each unit of blood product transfused carries independent TRALI risk

›Male-only donor plasma

›Observational data from multiple national programs show >50% TRALI incidence reduction

›Policy adopted in UK (2003), US (2014), and other countries

11Patient Discharge Instructions/pdi40

copy discharge instructions

›What happened to you

›You had a serious lung reaction to a blood transfusion called TRALI (Transfusion-Related Acute Lung Injury)

›This caused fluid to build up in your lungs making it hard to breathe

›This reaction happens when antibodies in the donated blood react with your lungs

›It is not your fault and it was not due to an error in giving you blood

›Your recovery

›Most people fully recover from this reaction within 2 to 4 days

›Your lungs should return to normal without permanent damage

›A follow-up chest X-ray will confirm your lungs have healed

›Important follow-up

›Return to your doctor or emergency department within 1-2 weeks

›Repeat chest X-ray to confirm the lung changes have resolved

›Lung function testing if you still feel short of breath

›Tell every healthcare provider about this reaction

›You had a serious transfusion reaction called TRALI

›It is essential this be documented before any future blood transfusions

›Future blood transfusions

›You may still require blood transfusions in the future if medically necessary

›Special blood products from male donors or pre-screened donors will be used

›Always remind your doctors and nurses about this reaction before any transfusion

›Return immediately to the emergency department if you experience

›Shortness of breath or difficulty breathing

›Even mild shortness of breath that is new or worsening

›Chest pain or tightness

›Any type of chest discomfort

›Rapid heart rate or palpitations

›Feeling your heart racing or pounding

12References/r26

Guidelines and key sources

›Primary evidence sources

›Toy P, Looney MR, Popovsky M, et al. Transfusion-Related Acute Lung Injury: 36 Years of Progress (1985-2021). Annals of the American Thoracic Society. 2022

›PMID 35045272 — comprehensive review of TRALI diagnostic criteria evolution

›Delaney M, Wendel S, Bercovitz RS, et al. Transfusion Reactions: Prevention, Diagnosis, and Treatment. Lancet. 2016

›PMID 27083327 — clinical management reference for all transfusion reactions

›Triulzi DJ. Transfusion-Related Acute Lung Injury: Current Concepts for the Clinician. Anesthesia and Analgesia. 2009

›PMID 19224781 — clinical decision-making reference

›Fang X, Mo C, Zheng L, et al. Transfusion-Related Acute Lung Injury: From Mechanistic Insights to Therapeutic Strategies. Advanced Science. 2025

›PMID 39836498 — most recent comprehensive mechanistic and therapeutic review

›Toy P, Gajic O, Bacchetti P, et al. Transfusion-Related Acute Lung Injury: Incidence and Risk Factors. Blood. 2012

›PMID 22117051 — incidence and two-hit model epidemiology

›Goldberg AD, Kor DJ. State of the Art Management of Transfusion-Related Acute Lung Injury (TRALI). Current Pharmaceutical Design. 2012

›PMID 22621274 — treatment rationale and contraindications evidence

Landmark trials and supporting studies

›Key trials informing TRALI management

›ARDSnet Trial (NEJM 2000) — lung-protective ventilation 6 mL/kg IBW reduces mortality by 22%

›Foundation for mechanical ventilation strategy in TRALI-associated ARDS

›PROSEVA Trial (NEJM 2013) — prone positioning reduces 28-day mortality in severe ARDS

›PaO2/FiO2 <=150 mmHg threshold for initiation

›FACTT Trial (NEJM 2006) — conservative fluid strategy improves oxygenation and reduces ventilator days in ARDS

›Supports restrictive fluid strategy in TRALI

›FLORALI Trial (NEJM 2015) — HFNC reduces 90-day mortality vs NIV in hypoxemic respiratory failure

›Supports HFNC as preferred initial escalation in non-intubated TRALI

›Semple JW, Rebetz J, Kapur R. Transfusion-Associated Circulatory Overload and Transfusion-Related Acute Lung Injury. Blood. 2019

›PMID 30808638 — TRALI vs TACO differentiation framework

›Vlaar APJ, Zwaginga JJ, Wiersum-Osselton JC. How I Diagnose and Treat Cardiorespiratory Complications of Transfusion. Blood. 2025

›PMID 39374519 — current diagnostic and therapeutic algorithm

Learn More: Transfusion-Related Acute Lung Injury (TRALI)→

Comprehensive Clinical Review

Structured, evidence-informed, long-form analysis for deeper understanding.

Evidence & Review

Reviewed by SymptomDx Medical Team · Last reviewed August 18, 2026

SymptomDx is an educational tool for medical professionals. It does not replace clinical judgment. Verify all clinical data and drug dosages with authoritative sources.